Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Metrics to compare | IVAA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIVAAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.8x | −2.6x | −0.5x | |
PEG Ratio | −0.07 | −0.01 | 0.00 | |
Price/Book | −35.0x | 1.1x | 2.6x | |
Price / LTM Sales | 147.8x | 11.0x | 3.2x | |
Upside (Analyst Target) | 87.9% | 175.2% | 44.7% | |
Fair Value Upside | Unlock | 11.0% | 5.7% | Unlock |